111292-75-2

Basic information

• Product Name: 2-Oxazolidinone, 3-(1-oxo-2-butenyl)-4-phenyl-, (E)-
• CAS NO: 111292-75-2
• Molecular Formula: C13H13NO3
• Molecular Weight: 231.251
• Mol File: 111292-75-2.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 3-(1-oxo-2-butenyl)-4-phenyl-, (E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 3-(1-oxo-2-butenyl)-4-phenyl-, (E)-(111292-75-2)
• EPA Substance Registry System: 2-Oxazolidinone, 3-(1-oxo-2-butenyl)-4-phenyl-, (E)-(111292-75-2)

Safety Data

• Hazardous Substances Data: 111292-75-2(Hazardous Substances Data)

Upstream product

• 623-68-7 trans-crotonic anhydride 
• 99395-88-7 (S)-4-phenyl-2-oxazolidinone 
• 623-68-7 crotonic anhydride 
• 20989-17-7 (2S)-2-phenylglycinol 
• 2935-35-5 (S)-2-phenylglycine 
• 625-35-4 trans-chrotonyl chloride 

Downstream Products

• 148706-31-4 (S)-3-((2S,3S)-2-Bromo-3-phenyl-butyryl)-4-phenyl-oxazolidin-2-one 
• 146137-33-9 (4S)-4-phenyl-3-(3-phenylbutanoyl)oxazolidin-2-one 
• 146137-34-0 (4S)-4-phenyl-3-<(3S)-3-phenylbutyryl>oxazolidin-2-one 
• 1610370-46-1 (S)-3-((4S,5R)-1-(4-((2'-fluoro-5'-methoxy-3-methylbiphenyl-4-yl)methyl)phenyl)-4-methyl-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazole-5-carbonyl)-4-phenyloxazolidin-2-one 
• 1432054-82-4 (4S)-3-{(2S)-2-[(S)-[3,5-bis(trifluoromethyl)phenyl](hydroxy)methyl]but-3-enoyl}-4-phenyl-1,3-oxazolidin-2-one 
• 1422637-16-8 (4S)-phenyl-3-[(3S)-((4S)-phenyl-2-thioxo-oxazolidin-3-yl)butyryl]oxazolidin-2-one 
• 1383790-39-3 C₂₃H₂₄N₂O₃S₂ 
• 1383790-40-6 C₁₉H₂₄N₂O₄S 
• 1245927-26-7 (4S,3'S)-3-[3'-(N,N-dibenzylamino)butanoyl]-4-phenyloxazolidin-2-one 
• 1245927-22-3 (4S,3'R,αR)-3-{3'-[N-benzyl-N-(α-methylbenzyl)amino]butanoyl}-4-phenyloxazolidin-2-one 

Relevant articles and documents

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

Nucleophilic halo-michael addition under lewis-base activation

A simple and general conjugate nucleophilic halogenation is presented. The THTO/halosilane combination has shown the ability to act as a nucleophilic halide source in the conjugate addition to a variety of Michael acceptors. In addition, a straightforward diastereoselective halogen installation using α,β-unsaturated acyloxazolidinones as platforms has been developed.

Palladium-Catalyzed Diastereoselective Synthesis of 3-Arylbutanoic Acid Derivatives

The first palladium-catalyzed diastereoselective conjugate addition of arylboronic acids to chiral imides is reported. The catalytic system employing 4-tert-butyloxazolidin-2-one as the chiral auxiliary in a mixed solvent system of MeOH/H2O (1:3) under an air atmosphere provides the optically active 3-arylbutanoic acid derivatives in excellent yields with high diastereoselectivity.